Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telomere crisis in leukemia

F Ishikawa1

  • 1Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan. fishikaw@bio.titech.ac.jp

International Journal of Hematology
|June 1, 1997
PubMed
Summary
This summary is machine-generated.

This study reviews telomere dynamics in leukemia, proposing the telomere crisis model to explain cancer cell evolution. It also discusses future anti-cancer agents targeting telomerase.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lattice dynamics and carrier recombination in GaAs/GaAsBi nanowires.

Scientific reports·2023
Same author

Polytypism in GaAs/GaNAs core-shell nanowires.

Nanotechnology·2020
Same author

Effects of growth temperature and thermal annealing on optical quality of GaNAs nanowires emitting in the near-infrared spectral range.

Nanotechnology·2019
Same author

Identification of a tumor-specific allo-HLA-restricted γδTCR.

Blood advances·2019
Same author

Superconductivity under pressure in the Dirac semimetal PdTe<sub>2</sub>.

Journal of physics. Condensed matter : an Institute of Physics journal·2019
Same author

Molecular beam epitaxial growth of dilute nitride GaNAs and GaInNAs nanowires.

Nanotechnology·2019
Same journal

Cytarabine-based induction and oral maintenance therapy for a single system with single-site Langerhans cell histiocytosis.

International journal of hematology·2026
Same journal

Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis.

International journal of hematology·2026
Same journal

Correction to: Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.

International journal of hematology·2026
Same journal

The efficacy of prophylactic tranexamic acid in patients with hematologic malignancy: a systematic review and meta-analysis.

International journal of hematology·2026
Same journal

Current status and challenges of TCR-T cell therapy for AML/MDS.

International journal of hematology·2026
Same journal

Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study.

International journal of hematology·2026
See all related articles

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Telomeres are protective caps on chromosomes.
  • Telomere length is critical in cellular aging and cancer.
  • Leukemia involves abnormal cell growth and telomere dysfunction.

Purpose of the Study:

  • To summarize existing research on telomere dynamics in leukemia.
  • To introduce the 'telomere crisis model' for cancer evolution.
  • To explore future therapeutic strategies targeting telomeres.

Main Methods:

  • Literature review of telomere dynamics in leukemia.
  • Conceptual framework development (telomere crisis model).
  • Discussion of emerging therapeutic targets.

Related Experiment Videos

Main Results:

  • Telomere shortening is a key factor in cancer development.
  • The telomere crisis model provides a framework for understanding leukemia's clonal evolution.
  • Telomerase inhibitors show promise as novel anti-cancer drugs.

Conclusions:

  • Telomere biology is central to understanding leukemia progression.
  • Targeting telomere maintenance mechanisms offers a promising therapeutic avenue.
  • Further research into telomerase inhibitors is warranted for cancer treatment.